INTRODUCTION
The distal hereditary motor neuropathies (distal HMN) usually presents as a classical peroneal muscular atrophy syndrome without sensory symptoms (1) . The overall clinical picture consists of progressive weakness and wasting of the extensor muscles of the toes and feet. Later on, weakness and wasting also involves the distal upper limb muscles. Foot deformity is a common feature. Often, unusual or additional features are present in 'complicated' distal HMN, including predominance in the hands, vocal cord paralysis, diaphragm paralysis and pyramidal tract signs. In some families several of these additional signs occur simultaneously. On clinical examination, distal HMN can hardly be distinguished from Charcot -Marie -Tooth (CMT) neuropathy (hereditary motor and sensory neuropathies, HMSN) because unequivocal sensory signs are often lacking in these disorders (2) . Therefore electrophysiological examinations are essential to support the diagnoses of CMT or distal HMN (3) . In one of the earliest reports on distal HMN, a family was described with an autosomal dominant mode of inheritance and onset in early adult life (4) . Also a kinship with autosomal recessive inheritance and isolated cases were reported (5) . By then, affected individuals with variable onset ages, ranging from infancy to adult life, were documented (1, 5) . To our knowledge, no pedigrees with a clear X-linked transmission were identified. In a population survey of peroneal muscular atrophies in North-East England, distal HMN accounted for 10% (6) . Based on age at onset, mode of inheritance and presence of additional features, a classification into seven subtypes was proposed (1, 5, 7) . The descriptions of these subtypes were often based on a limited number of affected individuals belonging to small families. However, with the introduction of genome-wide linkage studies several distal HMN families were studied in detail. In general, these studies nicely confirmed the previously delineated phenotypes but also showed considerable clinical and genetic heterogeneity. Also some distal HMN families did not fit into the existing classification and therefore represent novel clinical and genetic entities (8 -10) . Even clinically homogeneous distal HMN subtypes turn out to be genetically heterogeneous. Here we review the disease-causing genes that are currently known for dominant Human Molecular Genetics, Vol. 13 
SMALL HEAT SHOCK PROTEINS HSP22 AND HSP27
Small heat shock proteins (sHSP) or stress proteins are molecular chaperones induced in response to a wide variety of physiological and environmental factors (11) . Members of this superfamily share a conserved a-crystallin domain (12, 13) . Recently, a missense mutation (K141N) in the a-crystallin domain of the small heat shock 22 kDa protein 8 gene (HSPB8/HSP22 ) was reported in a Belgian distal HMN type II family linked to chromosome 12q24.3 (14, 15) . The same mutation was also found in an unrelated Czech distal HMN-II family. In two other distal HMN families (Bulgarian and English) a heterozygous transition involving the same lysine residue was found (K141E) (15) . Distal HMN-II has an onset between 15 and 25 years, and the presenting symptoms are paresis of the extensor muscles of the big toe and later of the extensor muscles of the feet. The disease progresses rapidly, and within 5 years a complete paralysis of all distal muscles of the lower extremities occurs (16) . Interestingly, missense mutations in the small heat shock 27 kDa protein 1 gene (HSPB1/HSP27 ) were also found to be associated with distal HMN (17) . Furthermore, one of the HSP27 mutations (S135F) was found in a Russian CMT2F family mapping to chromosome 7q11-q21 (18) , but this missense mutation was also present in an English distal HMN family (17) . This is an intriguing finding since in CMT2 sensory nerves are also involved (19, 20) . The affected individuals with mutations in HSP27 have a distal HMN phenotype with a variable onset age from juvenile to adulthood (M. Auer-Grumbach, D. Hilton-Jones, Z. Mitrovic and K. Talbot, personal communication). This suggests that these patients should also be classified as distal HMN-II (Table 1) . Most of the mutations in the HSP22 and HSP27 proteins target amino acids that are critical for the structural and functional integrity of the small HSP aAcrystallin (15, 17, 21) . Functional studies demonstrated that HSP22 and HSP27 are interacting partners (22, 23) and this interaction is increased between mutant proteins (15) . Mutant HSP22 or HSP27 showed a decreased viability of neuronal cells (15, 17) , and expression of mutant HSP22 in cultured cells promoted the formation of intra-cellular aggregates (15) . HSP27 was shown to be involved in the organization of the neurofilament network, which is important for the maintenance of the axonal cytoskeleton and transport (24) , and mutant HSP27 affects the neurofilament assembly (17) . This indicates that missense mutations in the HSP22 and HSP27 stress proteins lead to dysfunction of the axon cytoskeleton and axonal transport, relevant for the pathological mechanism in distal HMN. However, it is currently not known how these molecular chaperones act on other proteins involved in the motor neuron function.
GLYCYL tRNA SYNTHETASE (GARS)
Distal HMN type V is characterized by its peculiar distribution of muscle weakness and wasting, which starts and predominates in the upper limbs. The disease usually starts between the ages 5 and 20 years (1). Distal HMN-V was assigned to chromosome 7p in a single Bulgarian family (25) . Interestingly, a locus overlapping this region was found in a CMT family from Iowa in which hand muscle involvement was also a prominent feature. The disease, however, was designated as CMT2D since affected individuals also had sensory abnormalities (26) . In addition, a Mongolian family in which affected individuals had either distal HMN-V or CMT2D was reported to map to 7p15 (27) . The coincidence of distal HMN-V and CMT2D mapping to the same locus, and the similarity of clinical phenotypes with predominant hand involvement, had raised the question whether both neuropathies could be allelic and thus caused by different mutations within the same gene (25, 27) . Indeed, missense mutations in the glycyl tRNA synthetase gene (GARS ) in families with distal HMN-V and CMT2D were identified (28) , and confirm that both disorders are allelic ( Table 1 ). The aminoacyl tRNA synthetases are major protein components in the translation machinery, and are responsible for charging their associated tRNAs with the proper amino acid. How mutations in a housekeeping gene as GARS eventually lead to this neuropathy needs to be demonstrated. It is conceivable that neurons are more prone to a loss or decrease in tRNA synthetase, resulting in reduction of protein products reaching synaptic termini and suggesting a loss of function. However, GARS could also have an alternative function or interact with an unknown molecular partner in the peripheral nerve via a gain of function mechanism.
BERARDINELLI-SEIP CONGENITAL LIPODYSTROPHY (BSCL2 )
A large Austrian distal HMN family with a phenotype similar to the families described above was excluded from the disease locus on chromosome 7p, demonstrating genetic heterogeneity in distal HMN-V (29) . A genome-wide search in this family demonstrated linkage to chromosome 11q12 -q14. Interestingly, the linkage region overlaps with the locus for Silver syndrome, a complicated form of hereditary spastic paraplegia (SPG17) (30) . Individuals with Silver syndrome have spasticity of the legs accompanied by amyotrophy of the hands and occasionally also of the lower limbs (31) . Other families with Silver syndrome were reported in the literature (32 -34) , but it is unknown if these families link to 11q12 -q14. Recently, two missense mutations (N152S and S154L) were found in the Berardinelli-Seip congenital lipodystrophy (BSCL2 ) gene in the Austrian distal HMN family and in 16 additional families diagnosed as distal HMN or Silver syndrome (Table 1) (35) . Of interest is the observation that the same mutation can be associated with different phenotypes raising the possibility of a modifier effect (36) . Furthermore, null mutations in BSCL2, which encodes the protein seipin, have been identified in autosomal recessive BerardinelliSeip congenital lipodystrophy (37) . Little is known on the normal function of seipin, but it is an integral membrane protein of the endoplasmic reticulum. Mutant seipin affects protein glycosylation and results in aggregate formation, thereby leading to neurodegeneration in distal HMN-V or Silver syndrome (35) .
IMMUNOGLOBULIN m-BINDING PROTEIN 2 (IGHMBP2 )
Distal spinal muscular atrophy (SMA) with respiratory distress (SMARD1) is a severe autosomal recessive infantile neuropathy. The most prominent symptoms are diaphragmatic paralysis and predominant involvement of the upper limbs and distal muscles. This results in severe respiratory distress necessitating artificial ventilation (46) . Distal HMN-VI is synonymous to SMARD1, but clinically and genetically distinct from proximal SMA. The locus for distal HMN-VI was assigned to chromosome 11q13-q21 by homozygosity mapping in a Lebanese and German family (39) , and homozygous or compound heterozygous mutations were detected in the immunoglobulin m-binding protein 2 (IGHMBP2 ) gene (Table 1) (40) . Like the survival motor neuron (SMN1) protein, in which mutations cause proximal SMA (47), the IGHMBP2 protein co-localizes with the RNA-processing machinery in both the cytoplasm and the nucleus (48) . Interestingly, mutation of the mouse ortholog Ighmbp2 in the neuromuscular degeneration (nmd ) mouse leads to a neuromuscular degeneration resembling SMARD1 (49, 50) .
DYNACTIN (DCTN1 )
Families in which distal HMN is associated with unilateral or bilateral vocal cord paralysis were reported (51, 41) . This type corresponds to distal HMN type VII (1). The locus for distal HMN-VII was mapped to chromosome 2q14 in a Welsh family (41) . Recently, another distal HMN family was found to be linked to chromosome 2p13 (42) . This family showed a slowly progressive, autosomal dominant form of motor neuron disease without sensory symptoms. Onset of the disorder was in early adulthood with breathing difficulty due to vocal fold paralysis, progressive facial weakness, and weakness and muscle atrophy in the hands. In the gene encoding dynactin (DCTN1 ) a missense mutation (G59S) was found, and predicted to distort the folding of the dynactin microtubulebinding domain (42) ( Table 1 ). These findings indicate that dysfunction of the dynactin-mediated transport in the peripheral nerve can also lead to motor neuron disease.
SENATAXIN (SETX )
In 1964, an American family was reported as a variant of CMT neuropathy (52), but after re-evaluation of the phenotype the diagnosis was changed to autosomal dominant juvenile ALS, and the locus on chromosome 9q34 was designated ALS4 (43) . The disorder is characterized by juvenile-onset, slowly progressive distal limb amyotrophy and weakness starting in the lower limbs. Many had pyramidal tract signs including brisk reflexes and Babinski signs. Post-mortem examination showed severe loss of motor neurons in the brain stem and spinal cord (53) . Interestingly, distal HMN families were reported to be linked to the ALS4 locus on 9q34 (10) . The clinical phenotype in these families is strikingly similar to the original ALS4 family (53) , suggesting that ALS4 and distal HMN with pyramidal tract signs may be one and the same disorder (10). This was confirmed by the identification of missense mutations in the senataxin gene (SETX ) in the American ALS4 family and in two distal HMN families from Austria and Belgium (44) ( Table 1) . Although its function remains unknown, the senataxin protein contains a DNA/RNA helicase domain with strong homology to the IGHMBP2 protein involved in distal HMN-VI (40) and RENT1 (regulator of nonsense transcripts-1) (44). These genes encode proteins known to play roles in RNA processing. Interestingly, it was also shown that non-sense mutations in the SETX gene lead to the autosomal recessive ataxia-oculomotor apraxia type 2 (AOA2) (54) . These observations suggest that mutations in SETX may cause neuronal degeneration through dysfunction of the helicase activity or other steps in RNA processing (44) .
OTHER DISTAL HMN LOCI
In the study of Harding and Thomas, persons with autosomal recessive distal HMN were only mildly affected (19) , whereas Pearn and Hudgson described a much more severe phenotype in which wasting and weakness may extend to the proximal muscles in the legs and occasionally to the upper limbs (6) . These phenotypes are included in the distal HMN classification as distal HMN-III and distal HMN-IV, respectively (1). In an inbred Lebanese family, with onset at various ages, both distal HMN-III and -IV phenotypes occurred. The locus was mapped to chromosome 11q13 and suggest that the same disease gene could cause either childhood-or juvenileonset recessive distal HMN (38) . Diaphragmatic paralysis was also noted in some of the individuals who presented with childhood-onset. Interestingly, this locus overlaps with distal HMN-VI on 11q13 -q21 (39), and some clinical features were similar to distal HMN-VI (Table 1) . However, the IGHMBP2 gene, associated with distal HMN-VI (40), was excluded in the Lebanese family suggesting that both disorders are distinct clinical and genetic entities mapping to the same chromosomal region (38) . In addition, the high intra-familial variability raises the question of whether modifying genes could be involved in these disorders (38) . A novel form of autosomal recessive distal HMN was reported in consanguineous families living in the Jerash region of Jordan (45) . The onset of the disease is between 6 and 10 years of age, and is characterized by weakness and atrophy of the lower limbs associated with pyramidal features. Within 2 years the symptoms progress to the upper limbs. Homozygosity mapping was used to assign the distal HMNJerash (distal HMN-J) locus to chromosome 9p21.1 -p12 (8) . Also for this novel entity, the gene involved is currently unknown (Table 1) .
Congenital non-progressive distal SMA was not present in the original classification of distal HMN (1). This clinical entity was described in a family with mildly affected individuals suffering only from congenital weakness in the distal parts of the lower limbs, whereas more severely affected cases show in addition weakness of the pelvic girdle and muscles of the trunk resulting in scoliosis. This dominantly inherited disorder is also associated with arthrogryposis. Tendon reflexes are reduced or absent and sensory abnormalities are not found (55) . The gene for congenital non-progressive distal SMA with contractures was reported to map to chromosome 12q23 -q24 (Table 1 ) (9). The linkage region does not overlap with the distal HMN-II locus at 12q24.3 (56), but overlaps with the candidate interval for dominant scapuloperoneal SMA (SPSMA) (57) . No disease-causing gene has been identified for congenital non-progressive distal SMA. Genetic linkage to 12q23 -q24 was excluded in another dominant congenital benign HMN family and thereby suggesting genetic heterogeneity for this type of neuropathy (58) .
CONCLUSION
Early, clinical and genetic studies predicted that distal HMN is heterogeneous and at least seven subtypes were described (1, 7, 19) . Often the description of the phenotypes was based on isolated individuals or small families. Recent molecular genetic studies have confirmed the accuracy of this classification by showing that the clinical complexity has indeed a genetic basis. Even more, novel genetic and clinical entities were described in the process of mapping the different distal HMN loci (Table 1) . The molecular genetic studies have also stimulated the study of extended families leading to a finer delineation of the clinical phenotypes. Although distal HMN are clinically heterogeneous, most forms present as a pure motor neuropathy or neuronopathy (Fig. 1) . The distal HMN are related to other anterior horn cell disorders such as proximal SMA and ALS, since it was argued that the primary pathological process in distal HMN resides in the cell body of the anterior horn cell and not in the axons of the peripheral nerve (19) . However, by definition the distal HMN show a stereotyped symmetrical distal distribution of atrophy and weakness. To what extent the involvement is always exclusively motor is still a matter of debate since some minor sensory abnormalities have been described (3) . Furthermore, families with HMSN, in particular the axonal CMT neuropathy (CMT2), have been linked to some of the loci identified for distal HMN, and mutations in the genes involved can lead to distal HMN or CMT2 (Table 1, Fig. 1 ). It has now become evident that some distal HMN subtypes have unusual features or associated symptoms. Although these features and signs often show intra-familial variability, they represent essential hallmarks of particular distal HMN subtypes. Therefore, the study of additional persons in a family may be useful to clearly define the clinical distal HMN subtype.
The seven disease-causing genes identified so far for autosomal dominant and recessive distal HMN have diverse functions, and their expression is not restricted only to motor neurons. The first gene identified for a recessive form of distal HMN was IGHMBP2 (40). Interestingly, IGHMBP2 and SMN1 genes (causing proximal SMA) are involved in the pre-mRNA splicing machinery, a housekeeping function. SMN1 is involved in various cellular processes, including biogenesis of uridinerich small nuclear ribonucleoproteins, facilitating their cytoplasmic assembly into the spliceosome, pre-mRNA processing and activation of transcription (59) (60) (61) (62) (63) . Interestingly, the SETX gene, mutated in autosomal dominant distal HMN/ ALS4, has a helicase activity and is important for the RNA processing (44) . Mutations in GARS could affect protein synthesis which is also relevant for motor neuron maintenance and integrity (28) . Axonal transport of mRNAs for some of these genes may play an essential role in axon growth, synaptic function and cell viability of motor neurons (64) . The translation of specific proteins, including GARS, is relevant for the motor neuron which contains ribosome-like structures in distal axons and growth cones. Of interest to axonal transport is the function of the DCTN1 gene, which codes for a subunit of the dynactin complex required for dynein-mediated retrograde transport of vesicles and organelles along microtubules (42) . The recent identification of mutations in HSP22 and HSP27 in distal HMN provided the first evidence that mutations in sHSP play an important role in motor neuron disorders (15, 17) . The mutant small HSPs may lead to dysfunction of the axonal transport and dysregulate the cytoskeleton causing motor neuron death. Mutations in the small HSP genes, as well as in the BSCL2 gene, also result in aggresome formation suggesting a role for efficient protein folding (15, 35) .
Currently, there is no effective treatment for distal HMN. However, the involvement of small HSPs in distal HMN may open possibilities for therapy. Recent studies have shown that the HSP chaperones have anti-apoptotic and cytoprotective functions, and are often upregulated in neurodegenerative diseases (65 -68) . This means that modifying the expression of HSP22 or HSP27 might be a strategy to tackle distal HMN. It was recently shown that treatment with arimoclomol, a co-inducer of HSP, slows the process of motor neuron death, and thereby extends survival in the ALS mouse model (69, 70) . These findings indicate that molecules that upregulate HSPs, can not only be therapeutically beneficial for ALS but also for other neurodegenerative disease such as distal HMN. In addition, it was shown that HSP27 rescues pathological hyperphosphorylated tau-mediated cell death, thereby providing a neuroprotective effect in Alzheimer disease and other tauopathies (71) . Furthermore, HSP27 seems to have a protective effect against alpha-synuclein-induced cell death in Parkinson's disease (72) . So far only few mouse models with phenotypic resemblance to distal HMN were reported, providing opportunities to develop therapeutic approaches. One of these models is the progressive motor neuronopathy ( pmn ) (73, 74) . Pmn 2/2 null mice have a progressive motor neuronopathy, which becomes evident in the hind limbs and die from respiratory paralysis after a few weeks. Treatment with the ciliary neurotrophic factor prolonged survival, greatly improved the motor function and reduced the neural degeneration, even though treatment did not start until the first symptoms of disease had become apparent and substantial degenerative changes were already present (75) . Another example is the nmd mouse that is homozygous for autosomal recessive Ighmbp2 mutations (50) . As previously mentioned, the nmd mice phenotype resembles the human distal HMN-VI or SMARD1 condition (40) , and suffer from early progressive paralysis of the limbs and die from respiratory failure (49, 50) . Histopathological results showed progressive degeneration of motor neurons with secondary generalized atrophy of distal limb muscles (49) . In addition, reduced levels of Ighmbp2 in nmd mice compromise the integrity and function of motor neurons, skeletal myocytes and cardiac myocytes. These findings suggest that treatment of neurogenic muscular atrophy in the SMARD1 patients may reveal a similar role for IGHMBP2 in human cardiomyopathy (76) .
As a conclusion we refer to A.E. Harding: 'Our understanding of the nosology of these disorders will advance enormously when all the relevant gene(s) has been cloned' (1) .
